Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will present at the UBS Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, May 20, 2014, at 4:00 p.m. (ET). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -4.65%. On last trading day company shares ended up $6.36. Analysts mean target price for the company is $9.22. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -14.96%.
Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.02. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 0.94% in last trading session and ended the day on $6.43. ARNA gross Margin is 92.40% and its return on assets is -6.80%.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -7.22%.
The Rubicon Project (NASDAQ:RUBI) was upgraded by stock analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report issued on Wednesday, TheFlyOnTheWall.com reports. The firm currently has a $18.00 price objective on the stock, down from their previous price objective of $19.00. Oppenheimer’s target price would indicate a potential upside of 35.95% from the stock’s previous close. The Rubicon Project Inc. (NYSE:RUBI) shares moved down -8.38% in last trading session and was closed at $12.13, while trading in range of $11.81 – $13.52. The Rubicon Project Inc. (NYSE:RUBI) year to date (YTD) performance is -39.62%.
G&K Services, Inc. (NASDAQ:GK) announced that its Board of Directors has declared a quarterly dividend of $0.27 per share. The dividend will be payable on June 20, 2014 to shareholders of record at the close of business on June 4, 2014. G&K Services Inc. (NASDAQ:GK) ended the last trading day at $50.54. Company weekly volatility is calculated as 3.39% and price to cash ratio as 29.66.G&K Services Inc. (NASDAQ:GK) showed a negative weekly performance of -8.33%.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Monday said first-quarter loss widened to $18.4 million from $8.2 million last year. On a per-share basis, earnings were $0.85, compared to $2.84 last year. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) net profit margin is – and weekly performance is -5.66%. On last trading day company shares ended up $34.48. Analysts mean target price for the company is $77.33. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) distance from 50-day simple moving average (SMA50) is -28.24%.